Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

13 slides

Aeglea Biotherapeutics · Health & Biotech

About this deck

Explore the presentation slide by slide for its financial analysis, transaction details, and investor communications.

Read moreRead less
Company
Aeglea Biotherapeutics
Industry
Health & Biotech
Slides
13
Company
Aeglea Biotherapeutics
Industry
Health & Biotech
Slides
13
Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) Investment Banking Pitch Deck | Banker Decks